Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(α)anthracene-induced rat mammary carcinogenesis

Molecular Carcinogenesis

Volumn 52, Issue 5, 2013, Pages 359-369

  Chatterjee, Mary ^a   Das, Subhadeep ^a   Roy, Kaushik ^a   Chatterjee, Malay ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

5 lipoxygenase; Angiogenesis; Carcinogenesis; Cell proliferation; MMP 2; VEGF

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ARACHIDONATE 5 LIPOXYGENASE; GELATINASE A; LEUKOTRIENE B4; VASCULOTROPIN; ZILEUTON;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST; BREAST CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELL PROLIFERATION; FEMALE; HYDROXYEICOSATETRAENOIC ACIDS; LEUKOTRIENE B4; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MICROVESSELS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 84876099559     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21858     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Prentice RL, Sheppard L. Dietary fat and cancer: Consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990; 1: 81-97.
3. Fay MP, Freedman LS. Meta-analyses of dietary fats and mammary neoplasms in rodent experiments. Breast Cancer Res Treat 1997; 46: 215-223.
4. Ford-Hutchinson AW, Cresser M, Young RN. 5-Lipoxygenase. Annu Rev Biochem 1994; 63: 383-417.
5. Soumaoro LT, Iida S, Uetake H, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006; 12: 6355-6360.
6. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis 2005; 26: 785-791.
7. Shin VY, Jin HC, Ng EK, Sung JJ, Chu KM, Cho CH. Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth. Cancer Lett 2010; 292: 237-245.
8. Li N, Sood S, Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005; 11: 2089-2096.
9. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737-743.
10. Fischer AS, Metzner J, Steinbrink SD, et al. 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 2010; 161: 936-949.
11. Carter GW, Young PR, Albert DH, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991; 256: 929-937.
12. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2002; 68-69: 211-234.
13. Jing Z, Nan KJ, Hu ML. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1910-1916.
14. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-545.
15. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
16. Fang J, Yan L, Shing Y, Moses MA. HIF-1α-mediated upregulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001; 61: 5731-5735.
17. Crawford Y, Ferrara N. VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res 2009; 335: 261-269.
18. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
19. Huggins C, Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polynuclear hydro carbon and its suppression. Nature 1961; 189: 204-207.
20. McCormick DL, Philips JM, Horn TL, et al. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res 2010; 3: 73-81.
21. Nelson H, Kemp J, Berger W, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: A 3-month randomized controlled study. Ann Allergy Asthma Immunol 2007; 99: 178-184.
22. Imaoka T, Nishimura M, Teramoto A, et al. Cooperative induction of rat mammary cancer by radiation and 1-methyl-1-nitrosourea via the oncogenic pathways involving c-Myc activation and H-ras mutation. Int J Cancer 2005; 115: 187-193.
23. Ray RS, Ghosh B, Rana A, Chatterjee M. Suppression of cell proliferation, induction of apoptosis and cell cycle arrest: Chemopreventive activity of vanadium in vivo and in vitro. Int J Cancer 2006; 120: 13-23.
24. Yang P, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 385-395.
25. Braunhut SJ, Moses MA. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem 1994; 269: 13472-13479.
26. Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
27. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-S12.
28. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13, 610. Br J Pharmacol 2004; 142: 861-868.
29. Datta K, Biswal SS, Kehrer JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK 886, induces apoptosis independently of FLAP. Biochem J 1999; 340: 371-375.
30. Gugliucci A, Ranzato L, Scorrano L, et al. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. J Biol Chem 2002; 277: 31789-31795.
31. Kehrer JP, Biswal SS, La E, et al. Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886. Bichem J 2001; 356: 899-906.
32. Tu XK, Yang WZ, Shi SS, et al. 5-Lipoxygenase inhibitor zileuton attenuates ischemic brain damage: Involvement of matrix metalloproteinase 9. Neurol Res 2009; 31: 848-852.
33. Harris RR, Carter GW, Bell RL, et al. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol 1995; 17: 147-156.
34. Munoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997; 155: 1398-1403.
35. Ohshima H, Tatemichi M, Tomohiro S. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003; 417: 3-11.
36. Schetter AJ, Heegaard NHH, Harris CC. Inflammation and cancer: Interweaving micro RNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49.
37. Ye YN, Liu ESL, Shin VY, Wu WKK, Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004; 203: 179-188.
38. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001; 15: 2007-2009.
39. Anderson KM, Seed T, Vos M, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998; 37: 161-173.
40. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. J Gastroenterol 2003; 124: 57-70.
41. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007; 103: 24-32.
42. Kasayama S, Koga M, Kouhara H, et al. Unsaturated fatty acids are required for continuous proliferation of transformed androgen-dependent cells by fibroblast growth factor family proteins. Cancer Res 1994; 54: 6441-6445.
43. Hammamieh R, Jett M. Potential roles for inhibitors of arachidonic acid metabolism in prevention and treatment of breast cancer. Future Lipidol 2008; 3: 265-271.
44. Kort WJ, Bijma AM, Van Dam JJ, et al. Eicosanoids in breast cancer patients before and after mastectomy. Prostaglandins Leukot Essent Fatty Acids 1992; 45: 319-327.
45. Romano M, Catalano A, Nutini M, et al. 5-Lipoxygenase regulates malignant mesothelial cell survival: Involvement of vascular endothelial growth factor. FASEB J 2001; 15: 2326-2336.
46. 4 formation and prevents oral carcinogenesis in a 7, 12-dimethylbenz[α]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis 2008; 29: 2182-2189.
47. Melstrom LG, Bentrem DJ, Salabat MR, et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008; 14: 6525-6530.
48. Heffelfinger SC, Gear RB, Taylor K, et al. DMBA induced mammary pathologies are angiogenic in vivo and in vitro. Lab Invest 2000; 80: 485-491.
49. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001; 158: 735-743.
50. Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006; 26: 3579-3583.
51. Ye YN, Wu WKK, Shin VY, Cho CH. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur J Pharmacol 2005; 519: 52-57.
52. Hojilla CV, Wood GA, Khokha R. Metalloproteinases as common effectors of inflammation and extra cellular matrix breakdown in breast cancer. Breast Cancer Res 2008; 10: 205.